Personalized Medicine Versus The Public Health: FDA Debates The “Polypill”
This article was originally published in RPM Report
FDA is beginning to solicit input from the medical community on review issues for a multi-ingredient cardiovascular product designed to control hypertension, platelet aggregation and cholesterol levels. The key issue is whether convenience and broad access make up for loss of individualized dosing. That is an important debate in the era of personalized medicine.